⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for haematologic disease

Every month we try and update this database with for haematologic disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleNCT05280275
Multiple Myelom...
Neoplasms
Neoplasms, Plas...
Gammopathy, Mon...
Paraproteinemia...
Blood Protein D...
Haematologic Di...
Corneal Disease
Belantamab Mafo...
Daratumumab
Lenalidomide
Dexamethasone
18 Years - Hellenic Society of Hematology
Integrated Multiomics and Multilevel Characterization of Haematological Disorders and MalignanciesNCT04298892
Haematologic Di...
Haematological ...
clinical data a...
18 Years - Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell TransplantationNCT04180059
Haematologic Di...
CTL 19
18 Years - 75 YearsNantes University Hospital
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleNCT05280275
Multiple Myelom...
Neoplasms
Neoplasms, Plas...
Gammopathy, Mon...
Paraproteinemia...
Blood Protein D...
Haematologic Di...
Corneal Disease
Belantamab Mafo...
Daratumumab
Lenalidomide
Dexamethasone
18 Years - Hellenic Society of Hematology
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide RefractoryNCT05581875
Multiple Myelom...
Multiple Myelom...
Neoplasms
Gammopathy, Mon...
Paraproteinemia...
Blood Protein D...
Haematologic Di...
Corneal Disease
Neoplasms, Plas...
Belantamab Mafo...
Daratumumab
Pomalidomide
Dexamethasone
18 Years - Hellenic Society of Hematology
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleNCT05280275
Multiple Myelom...
Neoplasms
Neoplasms, Plas...
Gammopathy, Mon...
Paraproteinemia...
Blood Protein D...
Haematologic Di...
Corneal Disease
Belantamab Mafo...
Daratumumab
Lenalidomide
Dexamethasone
18 Years - Hellenic Society of Hematology
Integrated Multiomics and Multilevel Characterization of Haematological Disorders and MalignanciesNCT04298892
Haematologic Di...
Haematological ...
clinical data a...
18 Years - Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: